Free Trial

Pulse Biosciences (NASDAQ:PLSE) Trading Down 3.4% - Time to Sell?

Pulse Biosciences logo with Medical background

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report)'s stock price fell 3.4% during mid-day trading on Thursday . The company traded as low as $15.01 and last traded at $14.80. 99,122 shares were traded during trading, a decline of 46% from the average session volume of 184,770 shares. The stock had previously closed at $15.32.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Pulse Biosciences to a "sell" rating in a research note on Monday, March 31st.

Check Out Our Latest Stock Report on Pulse Biosciences

Pulse Biosciences Stock Performance

The company's 50 day moving average is $16.45 and its two-hundred day moving average is $17.52.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) earnings per share for the quarter.

Insiders Place Their Bets

In other news, CTO Darrin Uecker sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $16.40, for a total transaction of $246,000.00. Following the sale, the chief technology officer directly owned 137,872 shares of the company's stock, valued at $2,261,100.80. This represents a 9.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 71.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PLSE. Tower Research Capital LLC TRC raised its position in shares of Pulse Biosciences by 98.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock valued at $29,000 after buying an additional 838 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Pulse Biosciences by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company's stock worth $2,598,000 after acquiring an additional 1,092 shares during the last quarter. AlphaQuest LLC raised its position in Pulse Biosciences by 68.0% during the first quarter. AlphaQuest LLC now owns 3,116 shares of the company's stock valued at $50,000 after purchasing an additional 1,261 shares during the period. Rhumbline Advisers raised its position in Pulse Biosciences by 6.3% during the first quarter. Rhumbline Advisers now owns 27,375 shares of the company's stock valued at $440,000 after purchasing an additional 1,614 shares during the period. Finally, Farther Finance Advisors LLC lifted its stake in shares of Pulse Biosciences by 24.6% in the 1st quarter. Farther Finance Advisors LLC now owns 8,998 shares of the company's stock valued at $143,000 after purchasing an additional 1,778 shares during the last quarter. 76.95% of the stock is owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

(Get Free Report)

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

Further Reading

Should You Invest $1,000 in Pulse Biosciences Right Now?

Before you consider Pulse Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.

While Pulse Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore
AI Stocks Are Printing Money — These 3 Are Just Getting Started

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines